Annual Clinical Updates in Hematological Malignancies: Update on the Management of Diffuse Large B‑Cell Lymphoma

Cancer research · Diffuse large B-cell lymphoma

In the relapsed/refractory setting, there has been a rapid growth in the therapeutic armamentarium, including bispecific antibody combinations with chemotherapy, bispecific antibodies with antibody‑drug conjugates, and brentuximab vedotin + lenalidomide + rituximab.

Diffuse large B‑cell lymphoma (DLBCL) is the most common type of non‑Hodgkin lymphoma in the Western Hemisphere. First‑line therapy remains R‑CHOP or R‑CHP, with newer regimens for fit patients (pola‑R‑CHP or R‑CHOP + novel agents) and reduced‑intensity options for elderly or frail patients (R‑mini‑CHOP or palliation). High‑risk disease is being targeted with risk‑adapted approaches that incorporate cell‑of‑origin (COO) classification, interim PET imaging, and circulating tumour DNA (ctDNA). Second‑line curative‑intent strategies include CAR‑T cell therapy or autologous stem‑cell transplantation, while the relapsed/refractory setting has seen rapid expansion of bispecific antibodies, bispecific antibody‑chemotherapy combinations, antibody‑drug conjugates, and targeted therapy–antibody combinations. This review summarizes recent data and discusses ongoing efforts to improve the management of DLBCL.

This sentence demonstrates the current expansion of novel, highly targeted therapies beyond conventional chemotherapy for patients with relapsed or refractory diffuse large B‑cell lymphoma, highlighting the shift toward immune‑based strategies that may improve outcomes and broaden treatment options.

Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.

Original source

Related signals